Acella

Continental Technologies Ensure Greater Comfort and Safety in the Upper Mid-size Class

Retrieved on: 
Tuesday, April 23, 2024
Automotive Manufacturing, Consumer Electronics, Automotive, Technology, Manufacturing, Other Technology, General Automotive, Vehicle Technology, Software, Mobile, Wireless, Hardware, ECall, UWB, Comfort, Radio, Accident, Communication, Mercedes-Benz, PET, Acella, Transport, CCC, Mercedes-Benz E-Class, Mercedes-Benz Group, Friends, Bluetooth, Form W-9, Multimedia, Friction, Bluetooth Low Energy, Mobile phone

View the full release here: https://www.businesswire.com/news/home/20240423093593/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423093593/en/
    Mercedes-Benz is relying on numerous products and components from Continental in the new E-Class.
  • Furthermore, the technology company’s light control units ensure excellent road illumination thanks to intelligent control of the full LED headlights.
  • Continental develops pioneering technologies and services for sustainable and connected mobility of people and their goods.
  • In 2023, Continental generated sales of €41.4 billion, and currently employs around 200,000 people in 56 countries and markets.

A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup

Retrieved on: 
Monday, December 11, 2023
FDA, Pharmaceutical, Health, Pyridostigmine, ANDA, Food, Abbreviated New Drug Application, Acella, Patient, Multimedia, Myasthenia gravis, Neurology, Muscle weakness, Muscle fatigue, Generic drug, Pharmaceutical industry

Milla Pharmaceuticals Inc. , an A.forall company, announced that its partner, Acella Pharmaceuticals LLC , has just commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL.

Key Points: 
  • Milla Pharmaceuticals Inc. , an A.forall company, announced that its partner, Acella Pharmaceuticals LLC , has just commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL.
  • View the full release here: https://www.businesswire.com/news/home/20231211602217/en/
    Pyridostigmine Bromide Syrup is indicated for symptomatic treatment of myasthenia gravis.
  • This achievement marks the third ANDA commercialization for Milla Pharmaceuticals Inc. and the fourth for an A.forall product in the U.S. market.
  • With all other projects in our pipeline, our team looks forward to continuing that trend and turning our mission into reality.”
    Acella is excited to partner with Milla Pharmaceuticals on the commercialization of the Pyridostigmine Bromide Syrup.